The Dynamic Landscape of Global Deployment of Liquid Biopsy in Enabling Precision Medicine Minimal Residual Disease (MRD) Monitoring, Early Cancer Screening, and Personalized Treatment
Time: 5:30 pm
day: Day Two PM
Details:
- Fast-evolving liquid biopsy technologies and matrix (ctDNA, cfRNA, etc.)
- Clinical utilities and applications for minimal residual disease, early detection, etc.
- Harmonized assays and planning across varied regional regulations for global deployment
- AI/ML and real-world genomics data mining
